Cart
sales@molnova.com
Home - Products - Others - Other Targets - C14 Ceramide (d18:1/14:0)

C14 Ceramide (d18:1/14:0)

CAS No. 34227-72-0

C14 Ceramide (d18:1/14:0)( —— )

Catalog No. M34790 CAS No. 34227-72-0

C14 Ceramide (d18:1/14:0) is an endogenous ceramide produced by ceramide synthetase 6, which can be used for Parkinson's research.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 39 In Stock
5MG 64 In Stock
10MG 107 In Stock
25MG 180 In Stock
50MG 263 In Stock
100MG 390 In Stock
200MG 569 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock
Get Quotation Bulk Inquiry Add to Cart

Biological Information

  • Product Name
    C14 Ceramide (d18:1/14:0)
  • Note
    Research use only, not for human use.
  • Brief Description
    C14 Ceramide (d18:1/14:0) is an endogenous ceramide produced by ceramide synthetase 6, which can be used for Parkinson's research.
  • Description
    C14 Ceramide (d18:1/14:0) is an endogenous ceramide produced by ceramide synthetase 6, which can be used for Parkinson's research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    34227-72-0
  • Formula Weight
    509.85
  • Molecular Formula
    C32H63NO3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(=O)CCCCCCCCCCCCC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog
related products

  • GSK-626616

    GSK-626616 is a potent and orally bioavailable DYRK3 inhibitor (IC50: 0.7 nM). It inhibits other members of the DYRK family with similar potency. GSK-626616 is a potential therapy for the treatment of anemia.

  • tri-GalNAc-COOH

    Tri-GalNAc-COOH is a ligand for the asialoglycoprotein receptor (ASGPR) and is commonly used in lysosomal targeting chimera (LYTAC) investigations.

  • Nardosinone

    Nardosinone has inhibitory effect on Ang II-induced hypertrophy in H9c2 cells, might be mediated by targeting PI3K/Akt and MEK/ERK signaling pathways.

Sign In Join Free